Apimeds Pharmaceuticals US Inc (APUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,846 | -3,065 | -402 | -1,390 | -1,078 |
| Depreciation Amortization | 2 | -10 | N/A | 0 | N/A |
| Other Working Capital | -2,243 | -2,261 | 344 | 539 | 363 |
| Other Operating Activity | 1,980 | 1,953 | 38 | 117 | 82 |
| Operating Cash Flow | $-5,108 | $-3,381 | $-20 | $-734 | $-634 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -36 | -13 | N/A | 0 | N/A |
| Investing Cash Flow | $-36 | $-13 | $N/A | $0 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 250 | 250 | 250 | N/A | 250 |
| Common Stock Issued | 11,953 | 11,953 | N/A | N/A | N/A |
| Other Financing Activity | -76 | -76 | 17 | 327 | 0 |
| Financing Cash Flow | $12,127 | $12,127 | $267 | $327 | $250 |
| Beginning Cash Position | 4 | 4 | 4 | 410 | 411 |
| End Cash Position | 6,987 | 8,735 | 250 | 4 | 27 |
| Net Cash Flow | $6,983 | $8,732 | $247 | $-407 | $-384 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,108 | -3,381 | -20 | -734 | -634 |
| Capital Expenditure | -36 | -13 | N/A | N/A | N/A |
| Free Cash Flow | -5,144 | -3,395 | -20 | -734 | -634 |